Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Professors
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Tristan Ferry, MD, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Timothy Brennan, MD, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Toby A. Maurer, MD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Theodora Hatziioannou, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Tiffany Walker, MD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Teresa Evering, MD, MS
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Tamar Ginossar, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Tami P. Sullivan, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Timothy J. Wilkin, MD, MPH
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Tonia C. Poteat, PhD, MPH, PA-C
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Todd T. Brown, MD, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Page 3 of 39
«
1
2
3
4
5
...
10
20
30
...
»
Last »
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
June 8, 2026: HBV Reactivation During Tenofovir-Sparing ART
Which of the following statements is correct regarding the risk for hepatitis B virus (HBV) reactivation during tenofovir-sparing antiretroviral therapy (ART)?
A. Reactivation does not occur in individuals with documented positive hepatitis B surface antibody (HBsAb)
B. Reactivation should not occur if lamivudine (3TC) or emtricitabine (FTC) are included in the regimen
C. HBV DNA elevation that occurs during reactivation can resolve without resumption of tenofovir
D. Quantitative hepatitis B core antibody (HBcAb) titers predict the risk of HBV reactivation
View the Presentation
View the On-Demand Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE